• Home
  • 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC).

1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC).

Author List
R. Aggarwal, L. Trihy, E. Hernandez Romero, S. Luch Sam, M. Rastogi, I. De Kouchkovsky, E.J. Small, F. Feng, D. Kwon, T. Friedlander, H.T. Borno, R. Bose, J. Chou, V.S. Koshkin, A. Desai, S. Feng, A. Angelidakis, M.S. Johnson, L. Fong, T. Hope
Publication
Annals of Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/425026015
Publication Year
2022
Publication Title
R. Aggarwal, L. Trihy, E. Hernandez Romero, S. Luch Sam, M. Rastogi, I. De Kouchkovsky, E.J. Small, F. Feng, D. Kwon, T. Friedlander, H.T. Borno, R. Bose, J. Chou, V.S. Koshkin, A. Desai, S. Feng, A. Angelidakis, M.S. Johnson, L. Fong, T. Hope. 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep 1; 33:s1173.